The response to botulinum toxin type A was compared after two injection techniques in 45 patients with blepharospasm. Initially, patients were treated according to a triple injection technique; two injections into the upper eyelid and one injection into the lower eyelid. Subsequently, without altering the dose, the same patient group received two further injections into the pretarsal portion of the orbicularis oculi muscle of the upper lid. Triple injections were given in 227 treatments, of which 81% were successful. Mean duration of benefit was 8*5 weeks. Additional pretarsal injections were given in 183 treatment sessions. The number of successful treatments significantly increased, to 95% (P < 0.001), and the mean duration of benefit increased to 12-5 weeks (P < 0.001). Ptosis occurred significantly less often after pretarsal injections (P < 0.01). Patients with combined blepharospasm and involuntary levator palpebrae inhibition responded better to the pretarsal injection technique. (7 Neurol Neurosurg Psychiatry 1995;59:309-31 1) Patients and methods
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We studied 45 patients with blepharospasm who received BTA (Dysport) according to both injection techniques successively (table).
They had at least two treatments with known outcomes and a follow up of three years until the end of 1994. In 29 patients, EMG was performed from the levator palpebrae and orbicularis oculi muscles before or after the BTA treatment, to investigate the origin of eyelid movement disorder and the cause of unsatisfactory responses. The technique and the results have been reported earlier. 7 '0 The frequency and severity of spasms of the eyelids were both assessed on a five point scale, as two subcomponents of the blepharospasm rating scale reported by Fahn."' Patients were assessed before injection, and at each follow up visit only at the time of re-injection.
The effectiveness of treatment was based on the patient's report. A patient was considered as a poor responder or a non-responder if more than half of the treatments failed to improve the symptoms. The duration of beneficial effect was the period in weeks after the injection during which the patient noted improvement of symptoms. Initially, patients were re-treated after a fixed period (about Blepharospasm is characterised by intermittent or persistent involuntary eyelid closure due to spasmodic contractions of the orbicularis oculi muscles, '-6 (2) 27 (60) 4 (9) 1 (2) 23 (79) 2 (7) 4 (14) Unless otherwise stated, values are numbers of patients (%).
*Dry or watery eyes, photophobia, irritation, or pain in the eyes; telectromyographic recording was performed in 29 patients.
three months). If the patient returned before the previous injection had worn off, we did not assess the patient and did not inject BTA. Instead, we made a new appointment usually for four to six weeks later. Subsequently, we chose a more "open door" policy-that is, although a fixed appointment for re-injection was made, the patients could put their appointments either to an earlier date if symptoms had returned, or to a later date if the treatment was still effective. One vial of BTA containing 500 U was diluted with 5 ml of sterile saline. With the EMG as a guide, BTA was injected into the three components of the orbicularis oculinamely, the orbital, preseptal, and pretarsal portions. Initially, patients were treated according to the triple injection techniquetwo injections at the junction of the orbital and preseptal portions, medially and laterally in the upper lid and one injection laterally in the lower lid. A mean dose of 37 (range 8-85) U was injected on each side. Subsequently, the same patient group, without altering the total amount of BTA, received two injections into the pretarsal portion (a total of 10-15 U on each side), laterally and medially in the upper lid, in addition to triple injections. The data were statistically analysed by Wilcoxon matched pairs signed rank sum test.
Results
At the baseline level, about 95% of the patients exhibited forceful eyelid closure, which was present more than 50% of waking time. The mean values of the severity and frequency of spasms of the eyelids were 3'5 and 4-7 respectively.
Triple injections were given in 227 treatments, of which 186 were successful (81%). The mean duration of benefit was 8-5 weeks; 17% of the treatments resulted in ptosis and 2% in blurred vision. Five patients (11%) were poor responders or non-responders. Four of them had a better response after the pretarsal injections and EMG showed a combination of blepharospasm and involuntary levator inhibition in all. One patient with "pure" blepharospasm remained a nonresponder, even after the pretarsal injections. At the time of re-injection, 50% of the patients had forceful eyelid closure, and in 65% the involuntary movements were present more than 50% of waking time. The mean values of the severity and frequency of the spasms, 2-4 and 3-4 respectively, still differed significantly from those at the baseline level (P < 0.001).
Additional pretarsal injections were given in 183 treatments. The number of successful treatments significantly increased, to 175
(95%, P < 0-001). The mean duration of benefit also significantly increased, to 12-6 weeks (P < 0-001 The dramatic improvement of the response to pretarsal BTA application cannot be explained by the fact that the patients were already receiving treatment with BTA before they received additional pretarsal injections, because previous work has shown no increase in efficacy of BTA after repeated injections."2"3 There may, however, be some overestimation of the positive response to pretarsal injections because dropout patients, who did not respond to the triple injections and did not receive additional pretarsal injections, were not included. It is possible that these patients would not have responded to additional pretarsal injections either. Our unpublished data indicate that the overall successful treatment rate with additional pretarsal injections in the unselected total population of blepharospasm patients is about 85% to 90% of the total treatments.
The present study indicates that the activity of the pretarsal portion is probably more often disturbed in blepharospasm than has been assumed, as additional pretarsal injections of BTA increased the magnitude of favourable responses to the treatmnent in most of the patients. We assumed earlier'4 that the pretarsal motor units are probably showed that the recovery of type I muscle fibres from botulinum toxin is much faster than that of type II fibres. Therefore, it is possible that direct injection of BTA into the pretarsal portion would block more neuromuscular junctions and, hence, would prolong the period of effective paresis.
In conclusion, we suggest that additional injections of BTA into the pretarsal portion of orbicularis oculi muscles on the upper eyelid increase the magnitude of the response to BTA treatment and decrease the number of unsuccessful treatments and ptosis.
